Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC for active idiopathic inflammatory myopathy
NL-OMON55955Phase 3Recruiting
- Sponsor
- argenx
- Start
- Mar 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autoimmune Myopathies, dermatomyositis (DM), juvenile dermatomyositis (JDM) and 3 more comparing Efgartigimod PH20 SC plus background therapy with Placebo plus background therapy (2 arms). Primary endpoint: Total improvement score. Started Mar 2024; status: recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
Autoimmune Myopathiesdermatomyositis (DM)juvenile dermatomyositis (JDM)polymyositis (PM)antisynthetase syndrome (ASSD)
Beyond the preview
Go deeper on NL-OMON55955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55955.